You are here

  • Home
  • Archive
  • Volume 8, Issue 1
  • Correction: Apatinib plus camrelizumab (anti-PD1 therapy, SHR-1210) for advanced osteosarcoma (APFAO) progressing after chemotherapy: a single-arm, open-label, phase 2 trial

Article metrics

Article menu

See original article:

Download PDFPDF

XML
Correction
Correction: Apatinib plus camrelizumab (anti-PD1 therapy, SHR-1210) for advanced osteosarcoma (APFAO) progressing after chemotherapy: a single-arm, open-label, phase 2 trial

 

Online download statistics by month:

Online download statistics by month: June 2020 to November 2024

AbstractFullPdf
Jun 202005514
Jul 202003616
Aug 20200156
Sep 20200228
Oct 20200109
Nov 202001413
Dec 2020084
Jan 202101010
Feb 20210129
Mar 202101610
Apr 2021061
May 2021076
Jun 20210166
Jul 20210118
Aug 202101215
Sep 2021067
Oct 202101326
Nov 202101218
Dec 20210156
Jan 20220174
Feb 2022064
Mar 20220113
Apr 20220207
May 202202713
Jun 20220217
Jul 20220196
Aug 20220154
Sep 20220127
Oct 20220319
Nov 202201311
Dec 20220123
Jan 2023032
Feb 20230345
Mar 2023053
Apr 2023014
May 2023088
Jun 2023040
Jul 2023055
Aug 2023043
Sep 2023051
Oct 2023071
Nov 20230104
Dec 20230113
Jan 20240104
Feb 20240105
Mar 20240234
Apr 202401413
May 20240101
Jun 20240145
Jul 20240176
Aug 2024072
Sep 20240136
Oct 20240114
Nov 20240212
Total0726391